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Serological identiﬁcation of tumour antigens by recombinant expression cloning has proved to be an effective strategy for the
identiﬁcation of cancer-associated genes having a relevance to cancer aetiology and progression, and for deﬁning possible
targets for immunotherapeutic intervention. In the present study we applied this technique to identify immunogenic proteins
for gastric cancer that resulted in isolation of 14 distinct serum-reactive antigens. In order to evaluate their role in
tumourigenesis and assess the immunogenicity of the identiﬁed antigens, we characterised each cDNA clone by DNA
sequence analysis, mRNA tissue distribution, comparison of mRNA levels in cancerous and adjacent non-cancerous tissues and
the frequency of antibody responses in allogeneic patient and control sera. Previously unknown splice variants of TACC1 and
an uncharacterised gene Ga50 were identiﬁed. The expression of a newly identiﬁed TACC1 isoform is restricted to brain and
gastric cancer tissues. Comparison of mRNA levels by semi-quantitative RT–PCR revealed a relative overexpression of three
genes in cancer tissues, including growth factor granulin and Tbdn-1 – an orthologue of the mouse acetyltransferase gene
which is associated with blood vessel development. An unusual DNA polymorphism – a three-nucleotide deletion was found
in NUCB2 cDNA but its mRNA level was consistently decreased in gastric tumours compared with that in the adjacent non-
cancerous tissues. This study has revealed several new gastric cancer candidate genes; additional studies are required to gain a
deeper insight into their role in the tumorigenesis and their potential as therapeutic targets.
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Cancer development is a multistep process, during which the cell
acquires new phenotypic traits (overriding growth controls, induc-
tion of angiogenesis, evasion from host anti-tumour responses,
extravasation and growth at metastatic sites etc.) as a result of
successive genetic alterations (Hanahan and Weinberg, 2000). Iden-
tiﬁcation of genetic/epigenetic alterations that contribute to the
malignant phenotype capabilities is of major importance for the
understanding the molecular basis of cancer, deﬁning possible
targets for therapeutic intervention, prognosis and diagnosis of
human malignancies. Sahin et al (1995) introduced a novel
approach – serological identiﬁcation of tumour antigens by
recombinant expression cloning – called SEREX, for the identiﬁca-
tion of tumour antigens recognised by cancer patient auto-
antibodies. This strategy is based on the construction of cDNA
expression libraries from tumour specimens and immunoscreening
of the libraries with cancer patient sera, thus allowing a systematic
search for immunoreactive proteins (Sahin et al, 1995). SEREX has
been applied to multiple human tumours, including melanoma
(Jager et al, 2000a), renal cell cancer (Scanlan et al, 1999), astrocy-
toma (Sahin et al, 1995), breast (Jager et al, 1999) and colon
(Scanlan et al, 1998), identifying tumour antigens for each tumour
type, indicating that a humoral response is elicited in the majority
of cancer patients.
SEREX-deﬁned antigens represent a broad spectrum of structu-
rally and functionally diverse proteins – transcription factors,
adhesion molecules, signalling molecules, metabolic enzymes and
cDNA sequences of 1549 antigens have been deposited in the
SEREX database. Several categories of antigens have been detected
by SEREX i.e. shared cancer-testis (C-T) antigens, differentiation
antigens, mutated genes and translocation products, splice variant
products, overexpressed antigens, viral antigens, cancer-related and
cancer-independent autoantigens (Tureci et al, 1997; Sahin et al,
2001). Although the majority of the SEREX-identiﬁed genes have
not been characterised beyond the preliminary sequence analysis,
several of them have been proposed as attractive candidates for
the construction of anti-cancer vaccines. For instance, ‘cancer-
testis’ antigen NY-ESO-1 was identiﬁed by SEREX in oesophageal
cancer and is regarded as one of the most immunogenic tumour
antigens; antibody responses to NY-ESO-1 have been observed
in 40–50% of patients with NY-ESO-1 expressing tumours and
antibody production strongly correlates with CD8+ T cell
responses in these patients (Jager et al, 2000c). Clinical trials,
investigating the immunological effects of vaccination with NY-
ESO-1 peptides, are ongoing (Jager et al, 2000b). Several
previously known cytotoxic T cell targets, for example tyrosinase
and MAGE antigens, have been detected by SEREX, supporting
the premise of integrated CTL and B cell responses to tumour
antigens. Moreover, antibody responses to mutated p53 (Scanlan
et al, 1998), putative tumour suppressor ING1 (Jager et al,
1999) and ampliﬁed translation factor eIF-g4 (Brass et al, 1997)
have been detected by SEREX, thus demonstrating the potential
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cancer aetiology and may serve as diagnostic markers or indicators
of progression of the disease.
In the present study we applied SEREX to identify clinically rele-
vant cancer-associated genes in human gastric carcinoma, and to
deﬁne further the spectrum of immunogenic proteins in cancer.
Fourteen different antigens were recognised by cancer patients’ sera
and were further characterised by sequence analysis, mRNA expres-
sion pattern and reactivity with allogeneic sera.
MATERIALS AND METHODS
Tissue specimens and patient sera
Gastric cancer and the adjacent non-cancerous tissue specimens
were resected and snap frozen immediately after surgery. Tissue
specimens and sera were obtained from 20 gastric cancer patients
who had undergone surgical resection at the Latvian Oncology
Center after the informed written consent was obtained (the study
has been approved by the local ethical review board). In addition,
serum samples were obtained from stomach, colon, breast and
prostate cancer patients undergoing diagnostic procedures and
from healthy volunteers.
Construction of cDNA expression library
A cDNA expression library was constructed from a tumour
specimen of a moderately differentiated, ulcerated gastric
adenocarcinoma. Total RNA was isolated using Trizol reagent
according to manufacturer’s protocol (Life Technologies, Inc.).
Poly(A)
+ RNA was puriﬁed from total RNA using Dynabeads
mRNA Puriﬁcation kit (Dynal AS, Norway) and cDNA was ligated
into the lambda Uni-ZAP XR vector using Gigapack III Gold clon-
ing kit (Stratagene GmbH). After in vitro packaging, library
containing 2610
6 primary cDNA clones was obtained.
Immunoscreening
Immunoscreening of cDNA library was performed as described by
Sahin et al (1995). Brieﬂy, after one round of ampliﬁcation, the
cDNA library was screened with 1:250 diluted autologous
patient’s serum and allogeneic sera, which had been previously
preabsorbed with E coli-phage lysate. In order to eliminate cDNA
clones encoding human IgG, nitrocellulose membranes containing
phage plaques were pre-screened with AP-conjugated rabbit anti-
human IgG secondary antibody (Pierce, USA) and reactive plaques
were marked to exclude them from further study. Membranes
were then incubated with patients’ sera, and serum-reactive clones
were detected with AP-conjugated secondary antibody and visua-
lised by incubating with 5-bromo-4chloro-3-indolyl-phosphate
and nitroblue tetrazolium. The reactive phage clones were
subcloned to monoclonality and converted to pBluescript phage-
mids.
DNA sequencing and sequence analysis
Plasmid DNA was puriﬁed using QIAprep Spin Miniprep kit
(QIAGEN GmbH), analysed by EcoRI/XhoI restriction enzyme
digestion and clones representing different cDNA inserts were
sequenced using BigDye Terminator Cycle Sequencing Ready Reac-
tion kit on ABI PRISM 310 automatic sequencer (Applied
Biosystems). Gene-speciﬁc primers were designed to obtain full
insert sequences. cDNAs were identiﬁed by homology search
through GenBank (www.ncbi.nlm.nih.gov). Multiple sequence
alignments were performed with DNASIS (Hitachi Software Engi-
neering Co Ltd) and MACAW (NCBI) software. Chromosomal
localisation and exon–intron organisation for uncharacterised
cDNAs was determined by comparison to the working draft of
the human genome. Putative protein domains were predicted by
scanning the sequences against PROSITE and Pfam databases
(www.expasy.org and www-ludwig.unil.ch/SEREX).
Detection of antibodies in allogeneic sera
To assess frequencies of antibody responses to the SEREX-deﬁned
antigens in allogeneic sera, slightly modiﬁed immunoscreening
procedure was used. E coli were transfected directly on gridded
agar plate, by spotting 1 ml of monoclonal positive phage (20–
30 pfu ml
71) side by side with non-recombinant phages. ‘Phage
arrays’ were screened with 1:200 diluted allogeneic sera as
described above, excluding the IgG pre-screening step.
Comparative RT–PCR analysis
The mRNA expression pattern of SEREX-deﬁned antigens was
analysed by RT–PCR in a panel of normal tissue RNA from
whole brain, liver, heart, kidney, lung, trachea (Clontech),
spleen, colon, stomach, testes, ovary (Ambion), PBLs and a
specimen of gastric cancer and adjacent tissues. Relative mRNA
levels were compared between cancerous and adjacent non-
cancerous tissues by semi-quantitative RT–PCR. Total RNA
was isolated from paired tissue specimens using Trizol reagent
according to manufacturer’s protocol (Life Technologies, Inc.).
The ﬁrst-strand cDNA was synthesised from 4 mg of total
RNA primed with oligo-dT(18) and random hexamer primers
using First-Strand cDNA Synthesis Kit (Fermentas, Lithuania).
Gene speciﬁc PCR primers located within different exons were
designed to amplify cDNA fragments (300–400 bp in length)
of nine SEREX-deﬁned genes and GAPDH, b-actin and histone
H4 were used as internal standard genes. One ﬁftieth of RT
mixture was ampliﬁed in GeneAmp PCR System 2400 thermal
cycler (Perkin-Elmer Corp.) in a total reaction volume of
20 ml containing 10 pmole of each primer, 200 mM of dNTPs
and 2 U of Taq polymerase (Fermentas, Lithuania). Optimisation
of cycling conditions (amount of input cDNA and number of
cycles) was performed as described by Toh et al (1997). Ampli-
ﬁcation of all target genes was performed simultaneously, at the
same cycling conditions (1 min at 948C, 30 s at 588C, 45 s at
728C), except for the number of cycles that was determined
for each target gene (20 for b-actin, 25 for GAPDH, 27 for
Zg4, 28 for Ga55 and Ga19, 29 for Ga27, Ga50, Zg2, histone
H4 and 30 for Ga34, Zg14 and Zg15). Quantitative analysis of
RT–PCR products was performed densitometrically after scan-
ning the ethidium bromide stained gel on digital gel
documentation and analysis system GDS8000 (Ultra-Violet
Products Ltd, UK) and the intensities of bands were calculated
using GelWorks software. Standard curves of ampliﬁcation of
each target gene were constructed from series of PCRs with
ten 1.5-fold dilutions of normal stomach cDNA. Amounts of
PCR products were linearly dependent on input cDNA over
10-fold dilutions of cDNA. The relative amounts of each mRNA
were normalised to GAPDH and b-actin. The obtained values in
tumours (T) were compared to those in matched normal epithe-
lium (N) and T/N ratios were calculated for each mRNA from
each patient’s tissue samples. Each reaction was performed in
duplicate. Ratios 52o r40.5 (the mean values of two indepen-
dent experiments) were considered to represent signiﬁcant
alteration of expression levels.
5' and 3' RACE analysis
5' and 3' ends of full-length cDNAs were cloned from gastric
cancer and adjacent tissues using FirstChoise
TM RLM-RACE kit
(Ambion) according to manufacturer’s protocol. Brieﬂy, for clon-
ing of 5'-ends, 10 mg of total RNA was treated with Calf
Intestinal Phosphatase to remove 5'-phosphates from un-capped
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by Tobacco Acid Pyrophosphatase and RNA adapters were ligated
to mRNA molecules containing 5'-phosphate. A random-primed
reverse transcription and nested PCR with gene-speciﬁc and
adapter-speciﬁc primers were performed and products were cloned
using InsT/Aclone
TM PCR Product Cloning Kit (Fermentas,
Lithuania). For cloning of 3'ends, 1 mg of total RNA was reverse
transcribed using an oligo (dT)-anchored 3'RACE adapter and
nested PCR was performed.
RESULTS
Identiﬁcation of serum-reactive cDNA clones
Eleven serum-reactive clones were identiﬁed by immunoscreening
of approximately 8610
5 clones from gastric cancer cDNA expres-
sion library with autologous patient’s serum. In addition *3610
5
phage plaques were screened using allogeneic serum from a patient
with poorly differentiated inﬁltrative gastric adenocarcinoma,
resulting in the isolation of nine positive clones. Full insert
sequences of serum-reactive cDNA clones were obtained and iden-
tiﬁed by homology search through GenBank and SEREX databases.
This revealed that serum-reactive clones are derived from 14
distinct genes, including eight genes whose function is unknown
(listed in Table 1). Only two genes were detected by both autolo-
gous and allogeneic screening.
The frequency of antibodies from cancer patients and controls
reacting with SEREX antigens was determined. Seven of the anti-
gens had similar reactivity with serum from cancer patients and
control individuals, three antigens reacted exclusively with autolo-
gous patient serum, while four antigens reacted with several
cancer patient sera but not with sera from healthy individuals
(Table 2).
Analysis of sequence variations
Several sequence variations were found in three cancer-derived
cDNAs in comparison with GenBank entries. An alteration of
codon GAC (nt394) to GGC (Asp?Gly) in clone Ga34 (deposited
in GenBank, AY039241) encoding Endomucin2 (NM_016242) and
three scattered nucleotide insertions within the 136 bp region of
Zg14 (deposited in GenBank, AY039240) encoding for CGI-96
(AF151854), resulting in an altered 45 amino acid region in the
predicted protein sequence were also observed. However sequen-
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Table 1 Genes identiﬁed by SEREX analysis of gastric cancer
Clone Chr. location Gene symbol
a NCBI reference sequence Product, function, features, expression pattern
Genes isolated by autologous screening
Ga19
b 4 Tbdn-1 NM_025085 Orthologous to mouse tbdn-1acetyltransferase which is
involved in regulation of angiogenesis.
Ga27 17q21.32 GRN NM_002087 Epithelial cell growth factor granulin. Upregulated in brain
tumours and highly tumorigenic cell lines.
Ga28/Zg3 12 KIAA0373 NM_014684 Function unknown. Ubiquitously expressed
c.
Ga34
b 4p15.33–q24 Endomucin-2 NM_016242 Function unknown. Trans-membrane helix.
Ga44 5.5pter–q11 RARS NM_002887 Arginyl-tRNA synthetase. Aminoacylation of tRNA.
Ga50
b 12q12–12q14.3 HSPC232 NM_016488 Hypothetical protein. Function unknown. Multiple
alternatively spliced isoforms.
Ga52/Zg15 15q22–q24 KIAA1561 AB046781 Uveal auto-antigen; similar to dog’s C3VS protein, which
is upregulated in thyroid by TSH stimulation.
Ga55
b 8p11 TACC1 NM_006283 Transforming, acidic coiled–coil containing protein 1.
Involved in regulation of interaction between centrosomes
and microtubules.
Ga71 3q28 FXR1 NM_005087 Fragile X mental retardation-related protein 1.
Auto-antibodies are found in several auto-immune diseases.
Genes isolated by allogeneic screening
Zg2 15 KIAA0295 AB002293 Function unknown. Zinc ﬁnger C2H2 motif. Ubiquitously
expressed.
Zg4
b 11p15.1–p14 NUCB2 NM_005013 Ca
2+ binding protein. Contains DNA binding domain,
helix–loop–helix motif, acidic amino acid region, leucine
zipper and EF-hands.
Zg5 12 KIAA1164 AB032990 Partially similar to hypothetical protein KIAA1164.
Function unknown. Ubiquitously expressed
c.
Zg10 11p15 SWAP-70 AB014540 Involved in Ig heavy chain class switching. Expressed
predominantly in B lymphocytes.
Zg14
b 22q13.2–13.31 CGI-96 NM_015703 Function unknown. RNA recognition motif. Ubiquitously
expressed.
aHUGO approved gene symbols were used when available.
bThese cDNA sequences have been deposited in the GenBank (see text for accession numbers).
cAccording to RT–
PCR data at the Kazusa DNA Research Institute web-site (www.kazusa.or.jp).
Table 2 Reactivity of SEREX-deﬁned antigens with sera from healthy
donors and cancer patients
Clone
Healthy
donor
Gastric
Ca
a
Colon
Ca
Breast
Ca
Prostrate
Ca
Ga50 1/35 3/22 0/23 2/11 0/3
Ga52/Zg15 20/35 15/22 18/23 5/11 3/3
Ga55 0/35 1/22 0/23 0/11 0/3
Ga19 0/35 1/22 1/23 0/11 1/3
Ga27 0/35 1/22 0/23 0/11 0/3
Ga28/Zg3 4/35 3/22 1/23 3/11 2/3
Ga34 2/35 4/22 2/23 0/11 0/3
Ga44 0/35 3/22 0/23 1/11 0/3
Ga71 0/25 1/15 0/13 0/11 0/3
Zg2 1/25 2/22 0/23 0/11 0/3
Zg14 0/25 1/22 0/23 1/11 0/3
Zg4 0/25 2/22 0/23 0/11 0/3
Zg5 9/25 4/22 8/23 2/11 1/3
Zg10 3/25 4/22 2/23 2/11 0/3
aIncludes the reactivity with sera used for immunoscreening of the cDNA expression
library.
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epithelium and tissue samples of two other patients revealed the
same sequence variant for both genes, thus ruling out the possibi-
lity of somatic mutation in cancer cells.
Direct sequencing of NUCB2 cDNA derived from cancerous
tissue of the patient whose serum was used for allogeneic screening
showed heterogeneity of RT–PCR products at the 3' end of the
coding region which is not present in the clone Zg4. The RT–
PCR product was cloned into pTZ57R/T vector and two of ﬁve
clones sequenced had ACA deletion (submitted to GenBank,
AF450266). The 3-nucleotide deletion was also demonstrated by
sequencing of ampliﬁed genomic DNA fragment. As the normal
tissue sample from this patient was not available we could not
directly determine whether this deletion represent somatic muta-
tion or allelic polymorphism. Next we analysed DNA sequences
from tumour and adjacent tissue samples of ﬁve gastric cancer
patients, tumour and blood samples of ﬁve breast cancer patients
and from blood samples of 25 donors. All paired tissue specimens
had the same genotype thus showing that the deletion represents a
germline DNA polymorphism and likely is not an immunogenic
stimuli for production of anti-NUCB2 antibodies in the patients.
Nevertheless, all gastric cancer patients and two breast cancer
patients were heterozygous, one breast cancer patient had ACA
deletion on both alleles, however ﬁve of 25 donors were also
heterozygous at this locus, thus showing very high frequency of this
unusual polymorphism not only among cancer patients but also in
a general population.
Identiﬁcation of TACC1 and HSPC232 splice variants
Comparison of Ga55 cDNA (submitted to GenBank, AY039239)
with the published TACC1 sequence (GenBank, AF049910) showed
that Ga55 represents a TACC1 isoform generated by inclusion of
alternative 36 bp exon. The alternative exon is present in another
GenBank sequence (KIAA1103, AB029026) derived from brain
tissue, but is skipped in all other EST sequences, indicating that
TACC1 pre-mRNA splicing may be regulated in tissue speciﬁc
manner. The mRNA expression pattern of TACC1 isoforms was
analysed by RT–PCR in a panel of RNAs derived from normal
brain, liver, heart, kidney, lung, trachea, spleen, colon, stomach,
testis, ovary, PBLs and in gastric cancer and adjacent non-cancer-
ous tissue specimens using primers ﬂanking the alternative exon.
The transcript variant lacking the alternative exon was detected
universally in all tissues tested. In contrast, the transcript contain-
ing the 36 bp exon was strongly expressed in brain and gastric
cancer tissues; just trace amounts were detectable in lung and
colon, but not in normal stomach and other normal tissues
analysed (Figure 1). In subsequent analysis of paired gastric cancer
and normal tissues, inclusion of the alternative exon was detected
in three of 20 cancer tissue specimens but not in the adjacent
tissues.
Clone Ga50 represents a novel splice variant of uncharacterised
gene HSPC232. Alignment of GenBank cDNA entries and corre-
sponding ESTs revealed at least four transcript variants differing
in their 5' and 3' regions. RLM–RACE analysis showed that all
splice variants are expressed in gastric cancer and adjacent tissues,
and no additional variants were found. RT–PCR analysis showed
that the splice variants are universally expressed in normal tissues
but the efﬁciency of alternative splicing seems to be differentially
regulated in different tissues. However no signiﬁcant differences
in expression of the splice variants in gastric cancer and adjacent
tissues were found.
mRNA expression pattern of SEREX-identiﬁed antigens
Multiple matching EST sequences were found in GenBank/EMBL
databases for all of the identiﬁed antigens, however some genes
shared sequence identity only to ESTs derived from cancerous
tissues. Therefore, we analysed the mRNA tissue distribution of
selected antigens by RT–PCR in normal tissues (brain, liver, heart,
trachea, lung, kidney, spleen, colon, stomach, testis, ovary and
PBLs) and in gastric cancer and adjacent epithelium. Ga19, Zg15
and Zg4 mRNAs showed differential tissue distribution pattern.
Relatively high expression of Ga19 and Zg15 was observed in
normal testis, ovary, spleen, stomach, colon, and gastric cancer
while it was weak or undetectable in other tissues tested. Zg4
was predominantly expressed in spleen, testis and normal stomach
whereas RT–PCR signals were faint in all other tissues including
cancerous and adjacent non-cancerous tissues from a gastric cancer
patient (Figure 1).
Comparison of mRNA levels in cancerous and adjacent
normal tissues
In order to evaluate whether expression levels of genes encoding
SEREX-antigens are altered in cancer tissues, we compared the
relative mRNA levels in cancerous and paired non-cancerous
tissues by semi-quantitative RT–PCR. Expression levels of nine
genes isolated from gastric cancer cDNA library (Ga19, Ga27,
Ga34, Ga50, Ga55, Zg2, Zg4, Zg14, and Zg15) were analysed in
paired tissue samples from 20 gastric cancer patients. Relative
mRNA levels of target genes were normalised to GAPDH and b-
actin, and Tumour/Normal (T/N) ratios were calculated. Each T/
N value represents the mean value of two independent experiments
usually differing in less than 20%. T/N values 2 or 40.5 were
considered to represent signiﬁcant difference. Histone H4 cDNA
was ampliﬁed as a marker for the rate of proliferating cells in
the tissue sample. Relative overexpression of three genes in various
numbers of tumour specimens was observed. An example of the
RT–PCR results is shown in Figure 2. We observed 2.0–6.5-fold
increase in mRNA level of Ga19 in three of 20, 2.3–7.4-fold
increase of Zg15 in three of 20 and 2.3- and 2.9-fold increase of
Ga27 in two of nine gastric cancer specimens in comparison with
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Figure 1 Tissue distribution of Ga55 (TACC1), Ga19 (Tbdn-1), Zg4
(NUCB2) analysed by RT–PCR. Primers used were: Ga55 forward 5'-AC-
CCAAGAAGGCAAAGTCGC-3' and Ga55 reverse 5'-AAATCTGGGA-
GATCACTGCC-3'. The primers are ﬂanking the alternative exon –
demonstrating the presence of the two splice variants, 119 and 155 bp.
Ga19 forward primer 5'-CTAAAATCTATAAGCATGCTGG-3', Ga19
reverse 5'-ATTCATTGCTTTATAAGCCTGG-3', Zg4 forward 5'-
TCAAGCAAGTGATTGATGTGC-3', Zg4 reverse 5'-TCAGGATT-
CAGGTGG-TTTAGG-3', Fragment of GAPDH cDNA was ampliﬁed as
an internal control. 32, 29, 27, and 25 cycles of ampliﬁcation were used
for Ga55, Ga19, Zg4 and GAPDH, respectively. Ga Ca 3T and Ga Ca
3N – tumour and adjacent tissues from gastric cancer patient.
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b-actin). In the remaining cases, mRNA levels of these genes were
similar in cancer and non-cancerous tissues. Interestingly, 2–11-
fold downregulation of Zg4 was observed in 10 of 20 gastric cancer
specimens. The major drawback for measurement of the relative
abundance of cDNAs in clinical samples is the lack of an invariable
internal standard. Expression levels of commonly used standards
such as actins, tubulins and GAPDH may vary among different cell
types (Weisinger et al, 1999) and in response to various factors
such as hypoxia and, surgical resection (Thellin et al, 1999; Zhong
and Simons, 1999) etc. For example, we observed apparently
increased GAPDH mRNA levels in two tumour samples relative
to b-actin and to target genes, resulting in down-estimation of
the real expression levels of target genes when normalised to
GAPDH.
Sequence analysis of Ga19 cDNA
Sequence analysis of the Ga19 clone showed an uninterrupted ORF
throughout the insert sequence indicating that the cDNA repre-
sented by this clone is truncated at both 5' and 3'-ends. To obtain
the complete cDNA sequence RLM-RACE was performed. A single
fragment of 930 bp was obtained in 5'RLM–RACE analysis and
no variation of the transcription start site was found, but 3'RACE
yielded in an 850 bp product. The assembled cDNA sequence
contains 281 bp 5'UTR with several stop codons, 2595 bp coding
sequence and 206 bp 3'UTR (deposited in GenBank, AY039242).
Scanning of the predicted amino acid sequence against PROSITE
and Pfam databases revealed N-terminal acetyltransferase domain
(amino acids 250–602), bipartite nuclear localisation signal (aa
612–629) and TPR repeat region (aa 80–113; 46–181; 374–441).
DISCUSSION
Deﬁnition of all immunogenic proteins in cancer (‘cancer
immunome’) is regarded as the main long-term goal of SEREX
(Jager et al, 1999; Pfreundschuh, 2000). Four of 14 antigens
identiﬁed in the current study have been previously detected by
SEREX in various tumour types (Table 3), and two of the identi-
ﬁed genes – epithelial cell growth factor granulin (Lu and
Serrero, 2000; Liau et al, 2000) and transforming coiled coil
containing gene TACC1 (Still et al, 1999) have been previously
shown to be associated with cancer. A further gene – FXR1 is
autoantigen known to elicit antibody production in scleroderma
patients (Bolivar et al, 1998). Another isolated gene is an Agr-tRNA
synthetase. Autoantibodies against particular aminoacyl-tRNA
synthetases are frequently found in myositis, interstitial lung
disease, and artritis (Hirakata et al, 1999) and various tRNA
synthetases also have been detected by SEREX in renal (Scanlan
et al, 1999), breast (Jager et al, 1999) and prostate cancer, and T
cell leukemia (Itoh et al, 1999). No evidence for the implication
of the genes in cancer or autoimmune states has been reported
for the remaining antigens.
One possible reason for the immunogenicity of self-proteins is
structural changes, resulting from mutations, translocations or
the experiment of splice variants. Although we identiﬁed several
sequence variations in three tumour-derived cDNAs (NUCB2,
endomucin-2 and CGI-96), analysis of these sequences in tumour
and normal tissue specimens indicates that these variations repre-
sent allelic polymorphisms and are not likely to be associated
with the immunogenicity of these proteins. Nevertheless, three-
nucleotide deletion within the coding region of NUCB2 that we
detected with very high frequency among the cancer patients, is
very interesting ﬁnding. As a result of the deletion Gln is omitted
from the hydrophobic C-terminus of the protein. Moreover,
comparison of mRNA levels between cancerous and adjacent
non-cancerous tissues by RT–PCR showed that the expression of
NUCB2 is downregulated in 50% of gastric tumours. NUCB2 is
aC a
2+ binding protein, which also contains putative DNA binding
domain, two helix–loop–helix motifs, EF-hands and leucine
zipper (Barnikol-Watanabe et al, 1994; Kroll et al, 1999). It inter-
acts with the postmitotic growth suppressor necdin and is
proposed to be involved in the regulation of survival and death
of postmitotic cells by controlling Ca
2+ homeostasis in the cyto-
plasm (Taniguchi et al, 2000). Taken together, NUCB2 shows
some characteristics of tumour suppressor gene but further studies
investigating the functional signiﬁcance of the 3-nucleotide deletion
and downregulation of NUCB2 expression are required.
Alterations in the pattern and efﬁciency of alternative splicing of
several pre-mRNAs (e.g. CD44, BRCA1, WT-1) have been impli-
cated in tumorigenesis and correlate with tumour progression
(Cooper and Dougherty, 1995; Liu et al, 2001). De-regulation of
splice site selection may serve as an additional mechanism for
the generation of protein diversity contributing to the selection
of more aggressive tumour cells (Cooper and Mattox, 1997; Philips
and Cooper, 2000). We identiﬁed several previously unknown
splice variants of two genes – TACC1 represented by clone
Ga55, and uncharacterised gene HSPC232 represented by clone
Ga50. TACC1 is a recently identiﬁed gene, a member of TACC
protein family that is involved in the regulation of interaction
between centrosomes and microtubules (Gergely et al, 2000a).
Overexpression of TACC1 in mouse ﬁbroblasts results in cellular
transformation and anchorage independent growth (Still et al,
1999). In Drosophila embryos, overexpression of TACC domain
led to accumulation of microtubule asters and a complete failure
in development of the embryos (Lee et al, 2001). In contrast,
embryos carrying a mutation in d-tacc gene that decrease the level
of D-TACC protein have shorter centrosomal microtubules and
they also develop severe mitotic defects (Gergely et al, 2000b).
These data show that perturbation of TACC gene expression may
provoke various effects ranging from a genetic instability and
missegregation of chromosomes to cell death. In the current study
we identiﬁed a novel TACC1 isoform generated by inclusion of an
alternative 36 bp exon. This isoform was strongly expressed in
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Figure 2 Comparison of Ga19, Zg4 and Zg15 mRNA levels in
three paired gastric cancer (T) and adjacent epithelium (N) samples by
semi-quantitative RT–PCR. The same primers as shown in Figure 1
were used for ampliﬁcation of Ga19 and Zg4. Primers used for Zg15
were: forward primer 5'-TCTGGAACTATCTTTACCCAG-3', reverse
5'-GTTTGACGTGCTGAGCAAGC-3'. GAPDH and b-actin are used as
internal standards. Histone H4 is used as a marker for the rate of cell
proliferation.
Table 3 Antigens overlapping with previous SEREX analyses
TACC1 Stomach cancer (47)
SWAP70 (KIAA0640) Renal cell carcinoma (699;338), Hodgkin’s disease (765)
KIAA1561 Esophageal cancer (1558), breast carcinoma (1100),
hepatocellular carcinoma
KIAA0373 Testis/CTCL sera (2019)
SEREX database ID is shown in brackets
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tectable in the adjacent gastric epithelium and normal stomach
epithelium. From normal adult tissues it was predominately
expressed in brain. We propose that alteration in the pattern of
TACC1 mRNA splicing in cancer cells might lead to perturbation
of TACC1 function. Whether the ectopic expression of this isoform
served as a stimulus for antibody production in the patient also
remains to be established. Interestingly, TACC1 and TACC2 have
also have been detected by SEREX in gastric cancer by Yuichi
Obata (SEREX database).
The largest category of SEREX antigens occur as overexpressed
gene products. Gene ampliﬁcation, elevated transcription and
stability of mRNA or protein may lead to accumulation of protein
and induction of immune response by exceeding the number of
triggered TCRs required for T cell activation (Viola and Lanzavec-
chia, 1996; Lanzavecchia et al, 1999). In order to search for
overexpressed antigens, we used semi-quantitative RT–PCR to
examine the mRNA levels of the identiﬁed antigens in gastric
cancer and adjacent non-cancerous tissues. Relative overexpression
of Ga27 (granulin), Zg15 (orthologous of dog’s C3VS gene) and
Ga19 (orthologous to mouse Tbdn-1 gene) in gastric cancer was
observed. Upregulation of the growth factor granulin has been
shown in brain tumours (Liau et al, 2000) and in highly tumouri-
genic cell lines (Zhang and Serrero, 1998). Granulin has been
shown to have mitogenic activity in ﬁbroblasts, epithelial cells
and glioblastoma cell lines (Xu et al, 1998; Liau et al, 2000; Lu
and Serrero, 2000). Zg15 represents a human orthologue of dog’s
C3VS gene, its function is unknown but it is upregulated by mito-
genic stimulation in thyroid cells (Wilkin et al, 1996). Thus,
increased proliferation of tumour cells alone could account for
the overexpression of Zg15 in cancerous tissues. In theory, it could
be considered as a proliferation marker and its prognostic signiﬁ-
cance remains to be determined. Another gene that we found to
be upregulated in three of 20 gastric cancer specimens is human
orthologue of the mouse tbdn-1 gene encoding putative acetyl-
transferase. The levels and tissue distribution of tbdn-1 suggest
that it may be involved in regulation of vascular and hematopoietic
development and angiogenesis. Tbdn-1 is expressed at high levels at
day 8 of gestation, when yolk sac vasculogenesis and blood island
formation is peaking but downregulated at day 10 when formation
of larger coalesced vitelline vessels occurs. In adult mouse it is
expressed in atrial endocardium, bone morrow and ovarian follicles
only (Gendron et al, 2000). Although we observed relatively high
expression of Tbdn-1 in spleen, colon, stomach, testis and ovary,
it could be of interest to investigate which cell populations within
a tumour overexpress it and whether this acetyltransferase has a
role in tumour neovascularisation
In conclusion, a number of the antigens that we have identiﬁed
in this study may have a functional role in cancer aetiology or
progression, and the altered expression pattern of these genes
may provide the immunogenic stimuli in these patients. However
other possibilities, for example, unidentiﬁed mutations or altered
sub-cellular localisation which have been recently shown for b-
actin in apoptotic breast cancer cells (Hansen et al, 2001), cannot
be excluded. Further studies will be focused on exploration of the
possible functional differences between TACC1 isoforms, deﬁnition
of cell populations that express Tbdn-1 acetyltransferase and inves-
tigation of its possible role in tumour angiogenesis. It will also be
of interest to elucidate the possible role of NUCB2 in tumour
progression and the functional signiﬁcance of the peculiar three-
nucleotide polymorphysm. In addition, serological responses to
seven antigens (including TACC1, NUCB2, Tbdn-1 and granulin
etc.) were restricted to cancer patients and investigation of their
relevance for sero-diagnosis or prognosis is in progress.
ACKNOWLEDGEMENTS
We thank Dr O Tureci and Dr U Sahin for helping us to establish
the SEREX technique in our laboratories; Prof E Grens and Dr S
Mian for motivating discussions. This work was supported by
grants from Latvian Council of Science (No.2-2-011.1 and
01.0226), an UNESCO UVO-ROSTE grant, The John and Lucille
van Geest Foundation and The Cancer and Polio Research Fund.
Data deposition: cDNA sequences reported in this study have been
deposited in the GenBank (accession numbers AY039238–
AY039242 and AF450266).
REFERENCES
Barnikol-Watanabe S, Gross NA, Gotz H, Henkel T, Karabinos A, Kratzin H,
Barnikol HU, Hilschmann N (1994) Human protein NEFA, a novel DNA
binding/EF-hand/leucine zipper protein. Molecular cloning and sequence
analysis of the cDNA, isolation and characterization of the protein. Biol
Chem Hoppe Seyler 375: 497–512
Bolivar J, Guelman S, Iglesias C, Ortiz M, Valdivia MM (1998) The fragile-X-
related gene FXR1 is a human autoantigen processed during apoptosis. J
Biol Chem 273: 17122–17127
Brass N, Heckel D, Sahin U, Pfreundschuh M, Sybrecht GW, Meese E (1997)
Translation initiation factor eIF-4gamma is encoded by an ampliﬁed gene
and induces an immune response in squamous cell lung carcinoma. Hum
Mol Genet 6: 33–39
Cooper DL, Dougherty GJ (1995) To metastasize or not? Selection of CD44
splice sites. Nat Med 1: 635–637
Cooper TA, Mattox W (1997) The regulation of splice-site selection, and its
role in human disease. Am J Hum Genet 61: 259–266
Gendron RL, Adams LC, Paradis H (2000) Tubedown-1, a novel acetyltrans-
ferase associated with blood vessel development. Dev Dyn 218: 300–315
Gergely F, Karlsson C, Still I, Cowell J, Kilmartin J, Raff JW (2000a) The
TACC domain identiﬁes a family of centrosomal proteins that can interact
with microtubules. Proc Natl Acad Sci USA 97: 14352–14357
Gergely F, Kidd D, Jeffers K, Wakeﬁeld JG, Raff JW (2000b) D-TACC: a novel
centrosomal protein required for normal spindle function in the early
Drosophila embryo. EMBO J 19: 241–252
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57–70
Hansen MH, Nielsen H, Ditzel HJ (2001) The tumor-inﬁltrating B cell
response in medullary breast cancer is oligoclonal and directed against
the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc
Natl Acad Sci USA 98: 12659–12664
Hirakata M, Suwa A, Nagai S, Kron MA, Trieu EP, Mimori T, Akizuki M,
Targoff IN (1999) Anti-KS: identiﬁcation of autoantibodies to asparagi-
nyl-transfer RNA synthetase associated with interstitial lung disease. J
Immunol 162: 2315–2320
Itoh M, Watanabe M, Yamada Y, Furukawa K, Taniguchi M, Hata T, Schmitt
M, Ikeda H, Yamaguchi M, Ohno T, Nakashima K, Shiku H (1999) HUB1
is an autoantigen frequently eliciting humoral immune response in
patients with adult T cell leukemia. Int J Oncol 14: 703–708
Jager D, Stockert E, Jager E, Gure AO, Scanlan MJ, Knuth A, Old LJ, Chen YT
(2000a) Serological cloning of a melanocyte rab guanosine 5'-triphosphate-
binding protein and a chromosome condensation protein from a melano-
ma complementary DNA library. Cancer Res 60: 3584–3591
Jager D, Stockert E, Scanlan MJ, Gure AO, Jager E, Knuth A, Old LJ, Chen YT
(1999) Cancer-testis antigens and ING1 tumor suppressor gene product
are breast cancer antigens: characterization of tissue-speciﬁc ING1 tran-
scripts and a homologue gene. Cancer Res 59: 6197–6204
Jager E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J, Neumann A,
Rieckenberg J, Chen YT, Ritter G, Hoffman E, Arand M, Old LJ, Knuth
A (2000b) Induction of primary NY-ESO-1 immunity: CD8+ T lympho-
cyte and antibody responses in peptide-vaccinated patients with NY-
ESO-1+ cancers. Proc Natl Acad Sci USA 97: 12198–12203
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s
SEREX analysis of gastric cancer antigens
A Line ¯ et al
1829
ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(11), 1824–1830Jager E, Nagata Y, Gnjatic S, Wada H, Stockert E, Karbach J, Dunbar PR, Lee
SY, Jungbluth A, Jager D, Arand M, Ritter G, Cerundolo V, Dupont B,
Chen YT, Old LJ, Knuth A (2000c) Monitoring CD8 T cell responses to
NY-ESO-1: correlation of humoral and cellular immune responses. Proc
Natl Acad Sci USA 97: 4760–4765
Kroll KA, Otte S, Hirschfeld G, Barnikol-Watanabe S, Gotz H, Sternbach H,
Kratzin HD, Barnikol HU, Hilschmann N (1999) Heterologous overex-
pression of human NEFA and studies on the two EF- hand calcium-
binding sites. Biochem Biophys Res Commun 260: 1–8
Lanzavecchia A, Lezzi G, Viola A (1999) From TCR engagement to T cell acti-
vation: a kinetic view of T cell behavior. Cell 96: 1–4
Lee MJ, Gergely F, Jeffers K, Peak-Chew SY, Raff JW (2001) Msps/XMAP215
interacts with the centrosomal protein D-TACC to regulate microtubule
behaviour. Nat Cell Biol 3: 643–649
Liau LM, Lallone RL, Seitz RS, Buznikov A, Gregg JP, Kornblum HI, Nelson
SF, Bronstein JM (2000) Identiﬁcation of a human glioma-associated
growth factor gene, granulin, using differential immuno-absorption.
Cancer Res 60: 1353–1360
Liu HX, Cartegni L, Zhang MQ, Krainer AR (2001) A mechanism for exon
skipping caused by nonsense or missense mutations in BRCA1 and other
genes. Nat Genet 27: 55–58
Lu R, Serrero G (2000) Inhibition of PC cell-derived growth factor (PCDGF,
epithelin/granulin precursor) expression by antisense PCDGF cDNA trans-
fection inhibits tumorigenicity of the human breast carcinoma cell line
MDA-MB-468. Proc Natl Acad Sci USA 97: 3993–3998
Pfreundschuh M (2000) Exploitation of the B cell repertoire for the identiﬁ-
cation of human tumor antigens. Cancer Chemother Pharmacol 46(Suppl):
S3–S7
Philips AV, Cooper TA (2000) RNA processing and human disease. Cell Mol
Life Sci 57: 235–249
Sahin U, Li G, Tureci O, Pfreundschuh M (2001) Recognition of human
tumors: SEREX expression cloning to identify tumour antigens. In Cancer
Immunology, Robins RA, Rees RC (eds) pp 45–57. Dordrecht/Boston/
London: Kluwer Academic Publishers
Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner
F, Luo G, Schobert I, Pfreundschuh M (1995) Human neoplasms elicit
multiple speciﬁc immune responses in the autologous host. Proc Natl Acad
Sci USA 92: 11810–11813
Scanlan MJ, Chen YT, Williamson B, Gure AO, Stockert E, Gordan JD,
Tureci O, Sahin U, Pfreundschuh M, Old LJ (1998) Characterization of
human colon cancer antigens recognized by autologous antibodies. Int J
Cancer 76: 652–658
Scanlan MJ, Gordan JD, Williamson B, Stockert E, Bander NH, Jongeneel V,
Gure AO, Jager D, Jager E, Knuth A, Chen YT, Old LJ (1999) Antigens
recognized by autologous antibody in patients with renal-cell carcinoma.
Int J Cancer 83: 456–464
Still IH, Hamilton M, Vince P, Wolfman A, Cowell JK (1999) Cloning of
TACC1, an embryonically expressed, potentially transforming coiled coil
containing gene, from the 8p11 breast cancer amplicon. Oncogene 18:
4032–4038
Taniguchi N, Taniura H, Niinobe M, Takayama C, Tominaga-Yoshino K,
Ogura A, Yoshikawa K (2000) The postmitotic growth suppressor necdin
interacts with a calcium- binding protein (NEFA) in neuronal cytoplasm. J
Biol Chem 275: 31674–31681
Thellin O, Zorzi W, Lakaye B, De Borman B, Coumans B, Hennen G, Grisar
T, Igout A, Heinen E (1999) Housekeeping genes as internal standards: use
and limits. J Biotechnol 75: 291–295
Toh Y, Oki E, Oda S, Tokunaga E, Ohno S, Maehara Y, Nicolson GL, Sugi-
machi K (1997) Overexpression of the MTA1 gene in gastrointestinal
carcinomas: correlation with invasion and metastasis. Int J Cancer 74:
459–463
Tureci O, Sahin U, Pfreundschuh M (1997) Serological analysis of human
tumor antigens: molecular deﬁnition and implications. Mol Med Today
3: 342–349
Viola A, Lanzavecchia A (1996) T cell activation determined by T cell recep-
tor number and tunable thresholds. Science 273: 104–106
Weisinger G, Gavish M, Mazurika C, Zinder O (1999) Transcription of actin,
cyclophilin and glyceraldehyde phosphate dehydrogenase genes: tissue-
and treatment-speciﬁty. Biochim Biophys Acta 1446: 225–232
Wilkin F, Savonet V, Radulescu A, Petermans J, Dumont JE, Maenhaut C
(1996) Identiﬁcation and characterization of novel genes modulated in
the thyroid of dogs treated with methimazole and propylthiouracil. J Biol
Chem 271: 28451–28457
Xu SQ, Tang D, Chamberlain S, Pronk G, Masiarz FR, Kaur S, Prisco M,
Zanocco-Marani T, Baserga R (1998) The granulin/epithelin precursor
abrogates the requirement for the insulin-like growth factor 1 receptor
for growth in vitro. J Biol Chem 273: 20078–20083
Zhang H, Serrero G (1998) Inhibition of tumorigenicity of the teratoma PC
cell line by transfection with antisense cDNA for PC cell-derived growth
factor (PCDGF, epithelin/granulin precursor). Proc Natl Acad Sci USA
95: 14202–14207
Zhong H, Simons JW (1999) Direct comparison of GAPDH, beta-actin,
cyclophilin, and 28S rRNA as internal standards for quantifying RNA levels
under hypoxia. Biochem Biophys Res Commun 259: 523–526
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s
SEREX analysis of gastric cancer antigens
A Line ¯ et al
1830
British Journal of Cancer (2002) 86(11), 1824–1830 ã 2002 Cancer Research UK